Treatments nonadherent with American Thoracic Society guidelines by American Thoracic Society risk group
| I–II | IIIa | IIIb | IVa | IVb | |
| β-Lactams alone | 12 (100) | 36 (80.0) | 29 (90.6) | 1 (16.7) | 1 (3.6) |
| Other combinations not including a quinolone or a macrolide | 8 (17.8) | 2 (6.3) | 3 (50) | 4 (14.3) | |
| Macrolide alone | 1 (2.2) | 1 (3.6) | |||
| Other monotherapies | 1 (3.1) | ||||
| Quinolone alone | 2 (33.3) | 2 (7.1) | |||
| Non-antipseudomonal β-lactam plus a macrolide | 18 (64.3) | ||||
| Non-antipseudomonal β-lactam plus a quinolone | 2 (7.1) |
Data are presented as n (%).